Skip to main content

Find Clinical Trials

Home
Conditions
Lymphoma, T-Cell, Peripheral

Clinical trial condition

Lymphoma, T-Cell, Peripheral

Explore clinical trials studying Lymphoma, T-Cell, Peripheral. Study availability and eligibility vary by location and protocol.

235 public trials 60 recruiting studies

Refine in advanced search Browse all conditions

Lymphoma, T-Cell, Peripheral trial results

Not Yet Recruiting

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

NCT07209163

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

NCT07081607

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

NCT06385522

Conditions: Cutaneous T Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

NCT07032532

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Sun Yat-sen University Cancer Center Guanzhou, Guangdong, China

View Trial Details

Not Yet Recruiting

A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma

NCT06963632

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

NCT06757387

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

NCT06712173

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

NCT06702605

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

NCT06671717

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations: Peking University, Institute of Hematolgoy, Beijing, Beijing, China

View Trial Details

Not Yet Recruiting

A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

NCT06548347

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Not specified

View Trial Details